This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Alessandra Moscatelli
University of Milan
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Apolipoprotein A-I Milano (ApoA-IM) has been shown to significantly reduce coronary atherosclerotic plaques. However, the preparation of cost-effective pharmaceutical formulations of Apo A-I Milano can be limited by the high cost and difficulty of purifying the protein and producing the highly effective dimeric form. The aim of this study was the characterization of rice plants expressing the ApoA-I Milano protein primarily in a dimeric form, specifically in the seeds. The seed-specific 13 kDa rice-prolamin promoter drives the expression of ApoA-I Milano to different caryopsis tissues such as seed coat, aleurone cells, and endosperm, particularly into amyloplast and storage vacuoles. A plant-based ApoA-I Milano production system offers numerous advantages over current production systems, including direct production of the most therapeutically effective dimeric ApoA-I Milano forms, long-term storage of protein in seeds, and ease of protein production by simply growing plants. Therefore, seeds could provide a cost-effective source of ApoA-I Milano for use as a therapeutic.
Keywords
Apolipoprotein A-I Milano, seed-specific promoter, immunofluorescence, immunogold analyses.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jun, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Alessandra Moscatelli
University of Milan
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jun, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Apolipoprotein A-I Milano (ApoA-IM) has been shown to significantly reduce coronary atherosclerotic plaques. However, the preparation of cost-effective pharmaceutical formulations of Apo A-I Milano can be limited by the high cost and difficulty of purifying the protein and producing the highly effective dimeric form. The aim of this study was the characterization of rice plants expressing the ApoA-I Milano protein primarily in a dimeric form, specifically in the seeds. The seed-specific 13 kDa rice-prolamin promoter drives the expression of ApoA-I Milano to different caryopsis tissues such as seed coat, aleurone cells, and endosperm, particularly into amyloplast and storage vacuoles. A plant-based ApoA-I Milano production system offers numerous advantages over current production systems, including direct production of the most therapeutically effective dimeric ApoA-I Milano forms, long-term storage of protein in seeds, and ease of protein production by simply growing plants. Therefore, seeds could provide a cost-effective source of ApoA-I Milano for use as a therapeutic.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...